A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
Clinical trial NCT02875366 · COMPLETED
Trial details
- NCT number
- NCT02875366
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2017-09-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.